niclosamide has been researched along with Neoplasms in 15 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niclosamide is an oral antihelminthic drug used to treat parasitic infections in millions of people worldwide." | 4.98 | Niclosamide: Beyond an antihelminthic drug. ( Chen, W; Mook, RA; Premont, RT; Wang, J, 2018) |
| "Niclosamide is a drug used to treat parasitic infections." | 2.82 | Combination of niclosamide and current therapies to overcome resistance for cancer: New frontiers for an old drug. ( Ren, J; Wang, B; Wang, G; Wu, Q, 2022) |
| "Niclosamide is an FDA-approved anthelmintic drug for the treatment of parasitic infections." | 2.82 | Niclosamide as a Promising Therapeutic Player in Human Cancer and Other Diseases. ( Du, J; Liu, J; Ren, J; Wang, G; Wang, H; Wang, Z, 2022) |
| "The rapid development of new anticancer drugs that are safe and effective is a common goal shared by basic scientists, clinicians and patients." | 2.50 | Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. ( Arend, RC; Buchsbaum, DJ; Li, PK; Li, Y; Roberts, MJ; Samant, RS, 2014) |
| " Overall, the HG properties, together with its natural and eco-friendly composition, create a safe and efficient platform for the local treatment of non-resectable tumors or tumors requiring pre-surgical adjuvant therapy." | 1.72 | Smart and eco-friendly N-isopropylacrylamide and cellulose hydrogels as a safe dual-drug local cancer therapy approach. ( Abasolo, I; Andrade, F; Durán-Lara, EF; Hide, D; Llaguno, M; Martell, M; Oliva, M; Rafael, D; Raurell, I; Roca-Melendres, MM; Schwartz, S; Vijayakumar, S, 2022) |
| "Niclosamide is an oral anthelmintic drug, approved for use against tapeworm infections." | 1.62 | Nitro-Deficient Niclosamide Confers Reduced Genotoxicity and Retains Mitochondrial Uncoupling Activity for Cancer Therapy. ( Chen, S; Cheok, CF; Elfar, GA; Ho, YS; Hor, JH; Ngai, TW; Phua, N; Yeo, P, 2021) |
| "Developing drugs with anticancer activity and low toxic side-effects at low costs is a challenging issue for cancer chemotherapy." | 1.48 | Pathway-Based Drug Repositioning for Cancers: Computational Prediction and Experimental Validation. ( Akiyoshi, S; Hirose, L; Iwata, M; Kohara, H; Liao, J; Sawada, R; Tani, K; Yamanishi, Y, 2018) |
| "), indicating its great potential as an efficacious and orally bioavailable drug candidate for human cancer therapy." | 1.39 | Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. ( Chen, H; Chu, L; Ding, C; Liu, H; Shen, Q; Terry, K; Yang, Z; Zhang, Y; Zhou, J, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 6 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Chen, H | 1 |
| Yang, Z | 1 |
| Ding, C | 1 |
| Chu, L | 1 |
| Zhang, Y | 1 |
| Terry, K | 1 |
| Liu, H | 1 |
| Shen, Q | 1 |
| Zhou, J | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 3 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Iwata, M | 1 |
| Hirose, L | 1 |
| Kohara, H | 1 |
| Liao, J | 1 |
| Sawada, R | 1 |
| Akiyoshi, S | 1 |
| Tani, K | 1 |
| Yamanishi, Y | 1 |
| Ngai, TW | 1 |
| Elfar, GA | 1 |
| Yeo, P | 1 |
| Phua, N | 1 |
| Hor, JH | 1 |
| Chen, S | 1 |
| Ho, YS | 1 |
| Cheok, CF | 1 |
| Andrade, F | 1 |
| Roca-Melendres, MM | 1 |
| Llaguno, M | 1 |
| Hide, D | 1 |
| Raurell, I | 1 |
| Martell, M | 1 |
| Vijayakumar, S | 1 |
| Oliva, M | 1 |
| Schwartz, S | 1 |
| Durán-Lara, EF | 1 |
| Rafael, D | 1 |
| Abasolo, I | 1 |
| Ren, J | 2 |
| Wang, B | 1 |
| Wu, Q | 1 |
| Wang, G | 2 |
| Wang, Z | 1 |
| Du, J | 1 |
| Wang, H | 1 |
| Liu, J | 1 |
| Ma, R | 1 |
| Ma, ZG | 1 |
| Gao, JL | 1 |
| Tai, Y | 1 |
| Li, LJ | 1 |
| Zhu, HB | 1 |
| Li, L | 1 |
| Dong, DL | 1 |
| Sun, ZJ | 1 |
| Hartleben, G | 1 |
| Schorpp, K | 1 |
| Kwon, Y | 1 |
| Betz, B | 1 |
| Tsokanos, FF | 1 |
| Dantes, Z | 1 |
| Schäfer, A | 1 |
| Rothenaigner, I | 1 |
| Monroy Kuhn, JM | 1 |
| Morigny, P | 1 |
| Mehr, L | 1 |
| Lin, S | 1 |
| Seitz, S | 1 |
| Tokarz, J | 1 |
| Artati, A | 1 |
| Adamsky, J | 1 |
| Plettenburg, O | 1 |
| Lutter, D | 1 |
| Irmler, M | 1 |
| Beckers, J | 1 |
| Reichert, M | 1 |
| Hadian, K | 1 |
| Zeigerer, A | 1 |
| Herzig, S | 1 |
| Berriel Diaz, M | 1 |
| Chen, W | 1 |
| Mook, RA | 1 |
| Premont, RT | 1 |
| Wang, J | 1 |
| Barbosa, EJ | 1 |
| Löbenberg, R | 1 |
| de Araujo, GLB | 1 |
| Bou-Chacra, NA | 1 |
| Li, PK | 1 |
| Roberts, MJ | 2 |
| Arend, RC | 1 |
| Samant, RS | 1 |
| Buchsbaum, DJ | 1 |
| Lu, W | 1 |
| Lin, C | 1 |
| Waud, WR | 1 |
| Piazza, GA | 1 |
| Pan, JX | 1 |
| Ding, K | 1 |
| Wang, CY | 1 |
7 reviews available for niclosamide and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Combination of niclosamide and current therapies to overcome resistance for cancer: New frontiers for an old drug.
Topics: Antineoplastic Agents; Drug Delivery Systems; Humans; Neoplasms; Niclosamide; Water | 2022 |
Niclosamide as a Promising Therapeutic Player in Human Cancer and Other Diseases.
Topics: Anthelmintics; Humans; Neoplasms; Niclosamide; Signal Transduction; Vascular Diseases | 2022 |
Niclosamide: Beyond an antihelminthic drug.
Topics: Animals; Anthelmintics; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Disease Models, Animal; En | 2018 |
Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities.
Topics: Animals; Antineoplastic Agents; Drug Compounding; Drug Delivery Systems; Drug Repositioning; Humans; | 2019 |
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
Topics: Animals; Antineoplastic Agents; Humans; Molecular Targeted Therapy; Neoplasms; Neoplastic Stem Cells | 2014 |
Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Mechani | 2012 |
8 other studies available for niclosamide and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; D | 2013 |
Pathway-Based Drug Repositioning for Cancers: Computational Prediction and Experimental Validation.
Topics: Antineoplastic Agents; Computational Biology; Drug Repositioning; Neoplasms | 2018 |
Nitro-Deficient Niclosamide Confers Reduced Genotoxicity and Retains Mitochondrial Uncoupling Activity for Cancer Therapy.
Topics: DNA Damage; HCT116 Cells; Humans; Mitochondria; Neoplasms; Niclosamide | 2021 |
Smart and eco-friendly N-isopropylacrylamide and cellulose hydrogels as a safe dual-drug local cancer therapy approach.
Topics: Acrylamides; Cellulose; Doxorubicin; Humans; Hydrogels; Neoplasms; Niclosamide; Temperature | 2022 |
Injectable pegylated niclosamide (polyethylene glycol-modified niclosamide) for cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Liberation; Humans; Injections | 2020 |
Combination therapies induce cancer cell death through the integrated stress response and disturbed pyrimidine metabolism.
Topics: Antineoplastic Agents; Cell Death; Humans; Neoplasms; Niclosamide; Pyrimidines | 2021 |
Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; beta Catenin; Breast Neoplasms; Cell Line, Tumor; C | 2011 |